Hepatitis Home > Sofosbuvir

If you have chronic hepatitis C, your healthcare provider may recommend treatment with sofosbuvir. This prescription medicine comes as a tablet that is taken once daily for 12 to 48 weeks. It is approved for use in combination with other hepatitis C medications and works by interfering with the virus's ability to replicate. Insomnia, headaches, and nausea are some of the possible side effects.

What Is Sofosbuvir?

Sofosbuvir (Sovaldi™) is a prescription medication approved for the treatment of chronic hepatitis C in combination with one or two other medications -- ribavirin (Copegus®, Rebetol®, RibaPak®, Ribasphere®) and sometimes peginterferon alfa (Pegasys®, PEG-Intron®). The exact regimen will depend on the type of hepatitis C infection.
(Click What Is Sofosbuvir Used For? for more information, including possible off-label uses.)

Are There Side Effects?

Just like any medicine, sofosbuvir can cause side effects. However, not everyone who uses the drug will experience problems. Most people tolerate it quite well.
If reactions do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious side effects are less common.
Common side effects of sofosbuvir include but are not limited to:
(Click Sofosbuvir Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.